Loading...
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
BACKGROUND: Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg aspirin once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the prevention of cardiovascular events in patients with coronary artery disease and/or peripheral arterial disease. Howeve...
Na minha lista:
| Udgivet i: | Eur J Prev Cardiol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7457457/ https://ncbi.nlm.nih.gov/pubmed/32223323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2047487320913380 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|